Patents Assigned to Asuragen, Inc.
  • MIRNAS AS DIAGNOSTIC BIOMARKERS TO DISTINGUISH BENIGN FROM MALIGNANT THYROID TUMORS
    Publication number: 20130142728
    Abstract: Embodiments concern methods and compositions for distinguishing benign from malignant thyroid tumors in a patient based on the expression levels of one or more miRNAs.
    Type: Application
    Filed: October 27, 2012
    Publication date: June 6, 2013
    Applicant: Asuragen, Inc.
    Inventor: Asuragen, Inc.
  • Method of amplification of GC-rich DNA templates
    Patent number: 8409805
    Abstract: Methods are provided for increasing the processivity of DNA polymerases on GC-rich templates. The methods relate to providing enhancers and biased ratios of dNTPs, and may be used in DNA amplification reactions. The methods are useful for detecting genotypes associated with GC-rich repeats, including Fragile X Syndrome.
    Type: Grant
    Filed: February 13, 2009
    Date of Patent: April 2, 2013
    Assignee: Asuragen, Inc.
    Inventor: Gary J. Latham
  • Micrornas differentially expressed in cervical cancer and uses thereof
    Patent number: 8361714
    Abstract: The present invention concerns methods and compositions for identifying a miRNA profile for a particular condition, such as cervical disease, and using the profile in assessing the condition of a patient.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: January 29, 2013
    Assignee: Asuragen, Inc.
    Inventors: Sylvie Beaudenon-Huibregtse, Emmanuel Labourier, Laura Elizondo
  • Methods and compositions involving miRNA and miRNA inhibitor molecules
    Patent number: 8173611
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Grant
    Filed: November 14, 2005
    Date of Patent: May 8, 2012
    Assignee: Asuragen Inc.
    Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
  • Methods and compositions involving miRNA and miRNA inhibitor molecules
    Patent number: 8058250
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Grant
    Filed: August 10, 2007
    Date of Patent: November 15, 2011
    Assignee: Asuragen, Inc.
    Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
  • Methods and compositions involving MicroRNA
    Patent number: 8003320
    Abstract: The present invention concerns methods and compositions for isolating, enriching, and/or labeling miRNA molecules and for preparing and using arrays or other detection techniques for miRNA analysis. Moreover, the present invention concerns methods and compositions for generating miRNA profiles and employing such profiles for therapeutic, diagnostic, and prognostic applications.
    Type: Grant
    Filed: August 11, 2007
    Date of Patent: August 23, 2011
    Assignee: Asuragen, Inc.
    Inventors: David Brown, Kerri Keiger, Emmanuel Labourier, Jeffrey Shelton, Jaclyn Shingara
  • Methods of normalization in microRNA detection assays
    Patent number: 7993831
    Abstract: This application describes methods of quantifying a target miRNA in a biological sample by measuring the amounts of a target miRNA and at least one reference oncomir in a reaction volume, and normalizing the amount of target miRNA to the amount of one or more reference oncomirs.
    Type: Grant
    Filed: September 14, 2007
    Date of Patent: August 9, 2011
    Assignee: Asuragen, Inc.
    Inventors: Gary J. Latham, Heidi J. Peltier
  • Methods and compositions involving miRNA and miRNA inhibitor molecules
    Patent number: 7960359
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Grant
    Filed: August 10, 2007
    Date of Patent: June 14, 2011
    Assignee: Asuragen, Inc.
    Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
  • Methods and compositions involving microRNA
    Patent number: 7919245
    Abstract: The present invention concerns methods and compositions for isolating, enriching, and/or labeling miRNA molecules and for preparing and using arrays or other detection techniques for miRNA analysis. Moreover, the present invention concerns methods and compositions for generating miRNA profiles and employing such profiles for therapeutic, diagnostic, and prognostic applications.
    Type: Grant
    Filed: August 11, 2007
    Date of Patent: April 5, 2011
    Assignee: Asuragen, Inc.
    Inventors: David Brown, Kerri Keiger, Emmanuel Labourier, Jeffrey Shelton, Jaclyn Shingara
  • MIRNA BIOMARKERS OF LUNG DISEASE
    Publication number: 20110053158
    Abstract: This application describes miRNAs that may be used as serum or plasma biomarkers for characterizing lung disease in a patient. These miRNA biomarkers may be used alone or in combination with other markers for the diagnosis, prognosis, or monitoring of diseases such as lung cancer.
    Type: Application
    Filed: August 27, 2010
    Publication date: March 3, 2011
    Applicant: Asuragen, Inc.
    Inventors: Elizabeth MAMBO, David Brown, Alex T. Adai, Tiffany Sanford, Stephanie Volz, Ashish Choudhary
  • Methods and compositions involving microRNA
    Patent number: 7888010
    Abstract: The present invention concerns methods and compositions for isolating, enriching, and/or labeling miRNA molecules and for preparing and using arrays or other detection techniques for miRNA analysis. Moreover, the present invention concerns methods and compositions for generating miRNA profiles and employing such profiles for therapeutic, diagnostic, and prognostic applications.
    Type: Grant
    Filed: May 31, 2005
    Date of Patent: February 15, 2011
    Assignee: Asuragen, Inc.
    Inventors: David Brown, Kerri Keiger, Emmanuel Labourier, Jeffrey Shelton, Jaclyn Shingara
  • MIRNA BIOMARKERS OF PROSTATE DISEASE
    Publication number: 20100297652
    Abstract: This application describes miRNAs that may be used as serum or plasma biomarkers for characterizing prostate disease in a patient. These miRNA biomarkers may be used alone or in combination with other markers for the diagnosis, prognosis, or monitoring of diseases such as prostate cancer.
    Type: Application
    Filed: May 21, 2010
    Publication date: November 25, 2010
    Applicant: Asuragen, Inc.
    Inventors: Jeffrey Shelton, Kevin Kelnar, Stephanie Volz, Alex Adai, David Brown
  • METHODS AND COMPOSITIONS FOR DIAGNOSING AND MODULATING HUMAN PAPILLOMAVIRUS (HPV)
    Publication number: 20090258928
    Abstract: The present invention concerns methods and compositions for treating a patient having, suspected of having, or at risk of obtaining a HPV infection.
    Type: Application
    Filed: April 8, 2009
    Publication date: October 15, 2009
    Applicants: Asuragen, Inc., Northwestern University
    Inventors: Sylvie Beaudenon-Huibregtse, Laimonis Laimins, Laura Langfield, Gu Li, Emmanuel Labourier
  • miR-124 Regulated Genes and Pathways as Targets for Therapeutic Intervention
    Publication number: 20090192111
    Abstract: The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-124, using miR-124 to modulate a gene or gene pathway, using this profile in assessing the condition of a patient and/or treating the patient with an appropriate miRNA.
    Type: Application
    Filed: December 1, 2008
    Publication date: July 30, 2009
    Applicant: Asuragen, Inc.
    Inventors: Andreas G. Bader, Jason F. Wiggins, Lubna Patrawala, Kevin Kelnar, Mike Byrom, David Brown
  • MICRORNAS DIFFERENTIALLY EXPRESSED IN CERVICAL CANCER AND USES THEREOF
    Publication number: 20090186348
    Abstract: The present invention concerns methods and compositions for identifying a miRNA profile for a particular condition, such as cervical disease, and using the profile in assessing the condition of a patient.
    Type: Application
    Filed: September 12, 2008
    Publication date: July 23, 2009
    Applicant: Asuragen, Inc.
    Inventors: Sylvie Beaudenon Huibregtse, Emmanuel Labourier, Laura Elizondo
  • miR-15, miR-26, miR-31, miR-145, miR-147, miR-188, miR-215, miR-216, miR-331, mmu-miR-292-3P REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
    Publication number: 20090131356
    Abstract: The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-15, miR-26, miR-31, miR-145, miR-147, miR-188, miR-215, miR-216, miR-331, mmu-miR-292-3p, and using nucleic acid comprising all or part of the miR-15, miR-26, miR-31, miR-145, miR-147, miR-188, miR-215, miR-216, miR-331, mmu-miR-292-3p sequences to modulate a gene or gene pathway, using this profile in assessing the condition of a patient and/or treating the patient with an appropriate miRNA.
    Type: Application
    Filed: July 3, 2008
    Publication date: May 21, 2009
    Applicant: ASURAGEN, INC.
    Inventors: Andreas G. Bader, Mike W. Byrom, Lubna Patrawala, Charles D. Johnson, David Brown
  • Micrornas differentially expressed in leukemia and uses thereof
    Publication number: 20090092974
    Abstract: The present invention concerns methods and compositions for identifying a miRNA profile for acute myeloid leukemia (AML), and using the profile in assessing the condition of a patient.
    Type: Application
    Filed: December 10, 2007
    Publication date: April 9, 2009
    Applicant: ASURAGEN, INC.
    Inventors: Tim Davison, Dmitriy Ovcharenko, Jeffrey Shelton, Kevin Kelnar, David Brown